CD274 and renal cell carcinoma: Moreover, elevated TILs and PD1/PD-L1 signalings among metastatic lesions could provide additional supportive evidence for CN among patients with metastatic FH-RCC to achieve a more favorable response to PD-1/PD-L1-based immunotherapy.